Notable Facts
→Chief Development Officer at Glaukos Corp since April 2022
→Nearly 20 years experience in ophthalmic drug and medical device R&D
→PhD in Chemistry from University of North Carolina Chapel Hill
→Multiple patents and publications on ocular drug delivery
→Previously EVP at Nicox Ophthalmics and senior roles at Envisia Therapeutics
→Morehead Scholar at UNC Chapel Hill
→Serves on UNC Chemistry Department advisory board
→Originally from Prague, Czech Republic
→Co-authored peer-reviewed research on travoprost intraocular implants